The original version of this Article contained an error in the Abstract.
“While need for receptor antagonist (MRA) MRA after diagnosis suggests that a defined daily dose (DDD) of MRA between 12.5 and 50 mg may alleviate risk of death in a U-shape pattern”.
now reads:
“While the need for mineralocorticoid receptor antagonist (MRA) after diagnosis suggests that a defined daily dose (DDD) of MRA between 12.5 and 50 mg may alleviate risk of death in a U-shape pattern”.
This error has now been corrected in the PDF and HTML versions of the Article.
Additional information
The online version of the original article can be found at 10.1038/srep32103
Rights and permissions
This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
About this article
Cite this article
Wu, VC., Wang, SM., Chang, CH. et al. Correction: Corrigendum: Long term outcome of Aldosteronism after target treatments. Sci Rep 7, 45249 (2017). https://doi.org/10.1038/srep45249
Published:
DOI: https://doi.org/10.1038/srep45249
